首页 > 市场调查报告书 > 製药

神经疾病孤儿药

市场调查报告书

商品编码

1733853

2026 年至 2032 年格林-巴利综合症药物市场（按治疗类型、药物类别、分销管道和地区划分）

Guillain Barre Syndrome Drugs Market by Treatment Type, Drug Class, Distribution Channel, & Region For 2026-2032

出版日期: 2025年05月14日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

格林巴利症候群治疗市场评估 - 2026-2032

免疫疗法的进步和对罕见神经系统疾病的认识不断提高推动了格林-巴利综合症 (GBS) 治疗市场的发展。分析师估计，格林巴利症候群治疗市场规模将从 2024 年的 12 亿美元成长到 2032 年的 20.9 亿美元。

格林-巴利综合症药物市场的快速扩张主要归因于全球格林-巴利综合症发病率的增加、诊断能力的提高以及对新治疗方法研发的投资增加。这些因素将推动市场在 2026 年至 2032 年期间以 7.20% 的复合年增长率成长。

格林-巴利综合症药物市场定义/概述

格林巴利症候群是一种罕见的神经系统疾病，患者免疫系统会错误地攻击部分週边神经系统。这会导致肌肉迅速无力，甚至瘫痪。 GBS 药物市场包括用于治疗和控制该疾病症状的药物。

此外，格林-巴利综合症的主要治疗方法集中在减少免疫系统对神经系统的攻击并支持患者的康復过程。这通常涉及免疫球蛋白、血浆置换和支持性治疗。此外，还有各种药物可用于治疗格林-巴利症候群常伴随的某些症状，如疼痛、疲劳和忧郁。

推动格林-巴利综合症治疗市场成长的关键因素有哪些？

全球范围内格林-巴利综合症发病率的不断上升是寻求更好治疗方法的主要动力。世界卫生组织 (WHO) 估计，格林巴利症候群每年影响每十万人口中的 1 至 2 人，全球受影响人数总合超过 10 万人。越来越多的格林巴利症候群患者需要接受免疫球蛋白和血浆置换治疗。

免疫球蛋白 (IVIg) 疗法已成为治疗格林-巴利症候群最有效的方法，其日益普及正在刺激市场扩张。 2020年，美国国立卫生研究院（NIH）宣布，已开发国家超过80%的GBS病例采用IVIg疗法治疗。这种治疗剂的广泛使用正在推动市场对免疫球蛋白製剂的需求。

此外，用于早期检测格林巴利症候群的改进的诊断工具和更快的治疗可用性正在推动市场的发展。根据欧洲神经学会联合会（EFNS）的报告，由于电生理测试和脑脊髓液分析的进步，近年来诊断格林-巴利综合症的准确率提高了70％以上。早期准确的诊断对于有效治疗至关重要，从而推动了对格林-巴利综合症药物的需求。

影响格林-巴利综合症治疗市场采用的主要挑战是什么？

采用药物治疗格林-巴利综合症面临多项挑战，其中之一就是药物成本高。免疫球蛋白疗法是格林-巴利症候群的主要治疗方法，由于从人体血浆中获取免疫球蛋白製剂的製造过程十分复杂，因此费用昂贵。这构成了一个障碍，特别是对于那些无法获得先进医疗治疗的中低收入地区的患者而言。此外，高昂的药品成本对医疗保健造成压力，使得这些重要的治疗方法难以广泛普及且价格实惠。

另一个重大挑战是某些地区有效治疗方案有限。免疫球蛋白疗法和血浆置换被认为是格林-巴利症候群的标准治疗方法，但各国获得这些药物的机会并不统一。在医疗基础设施不发达的地区，这些药物的短缺和接收药物的延迟可能会对患者的治疗结果产生不利影响。此外，免疫球蛋白也用于治疗其他自体免疫疾病和神经系统疾病，导致全球需求增加，并引发影响格林-巴利症候群患者的供应限制。

此外，格林-巴利症候群的诊断很复杂，及时给药是一项挑战。格林-巴利综合症是一种罕见疾病，且进展迅速，因此早期诊断对于有效治疗至关重要。但肌肉无力和瘫痪等症状可能与其他神经系统疾病相似，这使得医疗保健提供者难以诊断。延迟识别格林-巴利综合症可能会导致错过及时使用免疫球蛋白或血浆置换治疗的机会，从而限制现有治疗方式的整体有效性，并可能使患者的预后恶化。这些诊断挑战也限制了GBS治疗在市场上的广泛使用。

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system. This leads to rapid-onset muscle weakness and, in some cases, paralysis. The GBS drugs market encompasses pharmaceutical products used to treat and manage the symptoms of this condition.

Furthermore, the primary treatments for GBS are focused on reducing the immune system's attack on the nervous system and supporting patients through the recovery process. This is typically achieved using immunoglobulins, plasma exchange, and supportive care. Additionally, various drugs are utilized to manage specific symptoms such as pain, fatigue, and depression that often accompany GBS.

What are the Key Drivers Propelling the Growth of the Guillain Barre Syndrome Drugs Market?

The increased global frequency of Guillain-Barre Syndrome is a primary driving force behind the quest for better treatments. The World Health Organization (WHO) estimates that GBS affects 1 to 2 persons per 100,000 people each year, totaling more than 100,000 cases worldwide. The increasing incidence of GBS cases necessitates treatments such as immunoglobulins and plasmapheresis.

Immunoglobulin (IVIg) therapy has emerged as the most effective treatment for GBS, and its growing popularity is fueling market expansion. In 2020, the National Institutes of Health (NIH) stated that IVIg therapy was used in more than 80% of GBS cases in developed countries. The extensive usage of this treatment is driving up demand for immunoglobulin goods in the market.

Furthermore, improved diagnostic tools for early detection of GBS have led to more prompt delivery of treatments, propelling the market. The European Federation of Neurological Societies (EFNS) reports that advances in electrophysiological testing and cerebrospinal fluid analysis have enhanced GBS diagnostic accuracy by more than 70% in recent years. Early and precise diagnosis is crucial for giving effective therapies, which drives demand for GBS medicines.

What are the Key Challenges Impacting the Adoption of Guillain Barre Syndrome Drugs in the Market?

The adoption of Guillain-Barre Syndrome (GBS) drugs faces several challenges, one of which is the high cost of treatment. Immunoglobulin therapies, which are the primary treatment for GBS, tend to be expensive due to the complex production process involved in deriving these products from human plasma. This creates barriers for patients, especially in low- and middle-income regions, where access to advanced healthcare treatments is limited. The high cost also puts pressure on healthcare systems, making it difficult to ensure the widespread availability and affordability of these critical treatments.

Another significant challenge is the limited availability of effective treatments in certain regions. While immunoglobulin therapies and plasmapheresis are considered the standard of care for GBS, access to these treatments is not uniform across all countries. In regions with underdeveloped healthcare infrastructures, there are shortages of these drugs or delays in treatment, which negatively affect patient outcomes. Additionally, the global demand for immunoglobulins has risen due to their use in other autoimmune and neurological disorders, leading to supply constraints and impacting GBS patients.

Furthermore, the diagnostic complexity of Guillain-Barre Syndrome poses a challenge to timely drug adoption. GBS is a rare and rapidly progressing condition, and early diagnosis is crucial for effective treatment. However, its symptoms-such as muscle weakness and paralysis-mimic other neurological conditions, making diagnosis difficult for healthcare providers. Delays in identifying GBS result in missed opportunities for timely treatment with immunoglobulins or plasmapheresis, limiting the overall efficacy of the available therapies and potentially worsening patient outcomes. These diagnostic challenges also hinder the overall uptake of GBS-specific drugs in the market.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Intravenous Immunoglobulin?

The intravenous immunoglobulin (IVIG) segment is estimated to dominate the market in the treatment type category during the forecast period. IVIG therapy is widely recognized as a first-line treatment for GBS due to its effectiveness in rapidly modulating the immune response. The ability of IVIG to reduce the severity and duration of GBS symptoms is making it a preferred choice among healthcare providers.

The relatively lower risk profile of IVIG compared to plasma exchange is also contributing to its dominance. IVIG treatment is associated with fewer complications and is generally better tolerated by patients, particularly those who are critically ill or have contraindications to plasma exchange.

Furthermore, the convenience of IVIG administration is noted as a factor driving its preference. The therapy is given in outpatient settings, reducing the need for prolonged hospital stays. This aspect is not only improving patient comfort but also potentially reducing overall treatment costs, making IVIG an attractive option for both patients and healthcare systems.

What are the Potential Factors for the Growth of Immunoglobulins in the Market?

The immunoglobulins segment is estimated to dominate the GBS drugs market in the drug class category during the forecast period. The proven efficacy of immunoglobulins in GBS treatment is the primary driver of this dominance. These drugs are + shown to effectively reduce the immune system's attack on the nervous system, leading to faster recovery and improved outcomes for patients.

The versatility of immunoglobulins in treating various autoimmune and inflammatory conditions is also contributing to their market leadership. The wide range of applications is driving increased production and availability of these drugs, potentially leading to economies of scale and improved accessibility for GBS patients.

Furthermore, ongoing research is conducted into novel formulations and administration methods for immunoglobulins. These innovations are aimed at enhancing efficacy, reducing side effects, and improving patient convenience. Such advancements are expected to further solidify the position of immunoglobulins in the GBS drugs market.

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Guillain barre syndrome drugs market during the forecast period. The growing prevalence of Guillain-Barre Syndrome in North America significantly drives the demand for effective treatments, including immunoglobulins and plasmapheresis. According to the Centers for Disease Control and Prevention (CDC), GBS affects approximately 3,000 to 6,000 people in the United States each year. The consistently high incidence rate of GBS fosters a robust market for therapies in the region.

The correlation between Zika virus infections and the onset of GBS has contributed to a growing demand for treatment options. In 2016, the CDC reported a surge in Zika virus infections in the United States and its territories, particularly in Florida, Puerto Rico, and Texas. In Puerto Rico alone, there were 61 confirmed cases of GBS linked to Zika virus infection. The spread of Zika and its association with GBS have heightened the demand for effective therapies.

Furthermore, North America's advanced healthcare infrastructure and support for rare disease research have accelerated the development of GBS treatments. In 2020, the National Institutes of Health (NIH) allocated more than $1.5 billion for neurological disorder research, which includes funding for rare diseases like GBS. This strong financial backing and institutional support drive innovations in GBS treatments, expanding the availability of drugs for patients.

How Do Government Initiatives Shape the Market Landscape in Europe?

Europe is estimated to exhibit significant growth within the GBS drugs market during the forecast period. Europe has witnessed a rising incidence of autoimmune disorders, including Guillain-Barre Syndrome, which drives the demand for treatments like immunoglobulins. According to a 2022 report from the European Academy of Neurology (EAN), approximately 1 to 2 individuals per 100,000 are diagnosed with GBS annually across Europe, translating to nearly 10,000 new cases each year. This increasing incidence boosts the demand for effective therapies.

Europe has seen a correlation between influenza outbreaks and the onset of GBS, prompting increased use of immunoglobulins and other therapies. According to the European Centre for Disease Prevention and Control (ECDC), influenza vaccines in 2021-2022 were linked to a 7% rise in GBS cases in some regions due to complications. The strong connection between influenza and GBS drives the need for accessible GBS treatments, particularly during the flu season.

Furthermore, European governments have prioritized rare diseases like GBS through various initiatives, driving the research and availability of treatments. The European Union's Orphan Drug Regulation has incentivized drug development for rare diseases since 2000. As of 2022, over 200 orphan medicinal products have been approved for rare diseases, including GBS, providing a significant boost to the GBS drugs market.

Competitive Landscape

The Guillain barre syndrome drugs market's competitive landscape is characterized by a varied range of large pharmaceutical companies and smaller specialized firms focusing on rare neurological disorders.

Some of the prominent players operating in the guillain barre syndrome drugs market include:

Grifols S.A.

CSL Behring

Shire (now part of Takeda Pharmaceutical Company)

Octapharma AG

Nihon Pharmaceutical Co., Ltd.

Akari Therapeutics, Plc

Hansa Biopharma AB

Biotest AG

China Biologic Products Holdings, Inc.

Kedrion Biopharma Inc.

Latest Developments

In July 2023, Grifols, a global leader in immunoglobulin therapies, announced a strategic partnership with the European Neurological Society to advance research on Guillain-Barre Syndrome (GBS) treatments. This collaboration aims to support clinical trials focusing on the efficacy of intravenous immunoglobulins (IVIg) in managing GBS symptoms and improving patient outcomes. The partnership is expected to accelerate the availability of enhanced GBS therapies across Europe.

In March 2022, Octapharma, a leading pharmaceutical company, launched a new clinical trial for its human plasma-derived immunoglobulin product in Europe, targeting patients with GBS. This trial is focused on evaluating the long-term benefits of IVIg treatments in reducing recovery time for GBS patients. Octapharma's trial is part of its broader strategy to expand its GBS drug portfolio in Europe.

1. Introduction

Market Definition
Market Segmentation
Research Methodology

2. Executive Summary

Key Findings
Market Overview
Market Highlights

3. Market Overview

Market Size and Growth Potential
Market Trends
Market Drivers
Market Restraints
Market Opportunities
Porter's Five Forces Analysis

4. Guillain-Barre Syndrome Drugs Competitive Market, By Drug Class

Immunoglobulins
Anticonvulsants
Antidepressants
NSAIDs
Opioids
Others

5. Guillain-Barre Syndrome Drugs Competitive Market, By Treatment Type

Intravenous Immunoglobulin
Plasma Exchange
Supportive Care

6. Guillain-Barre Syndrome Drugs Competitive Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Regional Analysis

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Asia-Pacific
China
Japan
India
Australia
Latin America
Brazil
Argentina
Chile
Middle East and Africa
South Africa
Saudi Arabia
UAE

8. Market Dynamics

Market Drivers
Market Restraints
Market Opportunities
Impact of COVID-19 on the Market

9. Competitive Landscape

Key Players
Market Share Analysis

10. Company Profiles

Grifols S.A.
CSL Behring
Shire (now part of Takeda Pharmaceutical Company)
Octapharma AG
Nihon Pharmaceutical Co., Ltd.
Akari Therapeutics, Plc
Hansa Biopharma AB
Biotest AG
China Biologic Products Holdings, Inc.
Kedrion Biopharma Inc.

11. Market Outlook and Opportunities

Emerging Technologies
Future Market Trends
Investment Opportunities

12. Appendix

List of Abbreviations
Sources and References

02-2729-4219

+886-2-2729-4219

License/价格

2026 年至 2032 年格林-巴利综合症药物市场（按治疗类型、药物类别、分销管道和地区划分）

Guillain Barre Syndrome Drugs Market by Treatment Type, Drug Class, Distribution Channel, & Region For 2026-2032

格林巴利症候群治疗市场评估 - 2026-2032

推动格林-巴利综合症治疗市场成长的关键因素有哪些？

影响格林-巴利综合症治疗市场采用的主要挑战是什么？

目录

第一章 引言

第二章执行摘要

第三章市场概述

4. 格林-巴利综合症药物的竞争市场（依药物类别）

5. 格林-巴利综合症药物的治疗类型竞争市场

6. 格林-巴利综合症药物的竞争市场（按分销管道划分）

第七章区域分析

第八章市场动态

第九章 竞争态势

第十章 公司简介

第十一章 市场展望与机会

第十二章 附录

Guillain Barre Syndrome Drugs Market Valuation - 2026-2032